{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:59:17Z","timestamp":1782910757020,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd002190.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000}}],"reference-count":278,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002190.pub6","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T13:37:19Z","timestamp":1671025039000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vaccines for the common cold"],"prefix":"10.1002","volume":"2022","author":[{"given":"Camila","family":"Montesinos-Guevara","sequence":"additional","affiliation":[{"name":"Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo; Universidad UTE; Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Buitrago-Garcia","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), Graduate School of Health Sciences; University of Bern; Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L","family":"Felix","sequence":"additional","affiliation":[{"name":"Departamento de Neonatolog\u00eda, Facultad de Ciencias de la Salud Eugenio Espejo; Universidad UTE; Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia V","family":"Guerra","sequence":"additional","affiliation":[{"name":"Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo; Universidad UTE; Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo; Universidad UTE; Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Martinez-Zapata","sequence":"additional","affiliation":[{"name":"Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo; Universidad UTE; Quito Ecuador"},{"name":"Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Simancas-Racines","sequence":"additional","affiliation":[{"name":"Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo; Universidad UTE; Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/archinte.1970.00310060059005","article-title":"Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease","volume":"125","author":"Griffin","year":"1970","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"100517","DOI":"10.1016\/j.eclinm.2020.100517","article-title":"Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial","volume":"27","author":"Abarca","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMoa2108903","article-title":"EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge","volume":"386","author":"Ahmad","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002190.pub6-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/ofid\/ofy210.1627","article-title":"A randomized, double-blind, placebo-controlled trial to assess the safety and tolerability of a respiratory syncytial virus (RSV) neutralizing monoclonal antibody (MK-1654) in healthy subjects","volume":"5","author":"Aliprantis","year":"2018","journal-title":"Open Forum Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2020","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1164\/rccm.201810-1921OC","article-title":"Local and systemic immunity against respiratory syncytial virus induced by a novel intranasal vaccine a randomized, double-blind, placebo-controlled clinical trial","volume":"200","author":"Ascough","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"30","key":"10.1002\/14651858.CD002190.pub6-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1016\/j.vaccine.2017.05.045","article-title":"A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age","volume":"35","author":"August","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/infdis\/145.3.311","article-title":"Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial","volume":"145","author":"Belshe","year":"1982","journal-title":"Journal of Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD002190.pub6-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1128\/jcm.30.8.2064-2070.1992","article-title":"Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children","volume":"30","author":"Belshe","year":"1992","journal-title":"Journal of Clinical Microbiology"},{"issue":"12","key":"10.1002\/14651858.CD002190.pub6-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1086\/425981","article-title":"Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children","volume":"190","author":"Belshe","year":"2004","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1086\/381184","article-title":"Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old","volume":"189","author":"Belshe","year":"2004","journal-title":"Journal of Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/infdis\/jiy065","article-title":"Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials","volume":"217","author":"Beran","year":"2018","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/157591b0","article-title":"Trial of an oral vaccine against bacterial infection accompanying the common cold","volume":"157","author":"Bourne","year":"1946","journal-title":"Nature"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"2073\u201381","DOI":"10.1093\/cid\/ciz653","article-title":"First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral vector\u2013expressing RSV fusion, nucleocapsid, and antitermination viral proteins in healthy adults","volume":"70","author":"Cicconi","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1128\/jcm.29.6.1175-1182.1991","article-title":"Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees","volume":"29","author":"Clements","year":"1991","journal-title":"Journal of Clinical Microbiology"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"ofz212","DOI":"10.1093\/ofid\/ofz212","article-title":"Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is overattenuated","volume":"6","author":"Cunningham","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"19","key":"10.1002\/14651858.CD002190.pub6-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"Suppl","key":"10.1002\/14651858.CD002190.pub6-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ofid\/ofz359.061","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a single immunization of AD26.RSV.Pref against RSV infection in a viral challenge model in healthy adults","volume":"6","author":"DeVincenzo","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"5322","key":"10.1002\/14651858.CD002190.pub6-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/bmj.1.5322.34","article-title":"Some attempts to produce an experimental vaccine with rhinoviruses","volume":"1","author":"Doggett","year":"1963","journal-title":"British Medical Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002190.pub6-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1093\/ofid\/ofx162.089","article-title":"A\u00a0single dose monoclonal antibody (mAb) immunoprophylaxis strategy to prevent RSV disease in all infants: results of the first in infant study with MEDI8897","volume":"4","author":"Domachowske","year":"2017","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Domachowske JB Khan AA Jensen K Takas T Villafana T Dubovsky F A single dose monoclonal antibody immunoprophylaxis strategy to prevent respiratory syncytial virus disease in all infants: results of the first in infant study with MEDI8897 Pediatrics 2018 141 1 256 10.1542\/peds.141.1_MeetingAbstract.256","DOI":"10.1542\/peds.141.1MA3.256"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1128\/iai.5.3.295-299.1972","article-title":"Enteric immunization with live adenovirus type 21 vaccine I. Tests for safety, infectivity, immunogenicity, and potency in volunteers","volume":"5","author":"Dudding","year":"1972","journal-title":"Infection and Immunity"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12967-019-2040-y","article-title":"A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections","volume":"17","author":"Esposito","year":"2019","journal-title":"Journal of Translational Medicine"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0024|cit24","unstructured":"A phase II, double-blind placebo-controlled study to determine the prophylactic efficacy of oral BTA798 in an experimental rhinovirus challenge model trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2008%E2%80%90001714%E2%80%9024%E2%80%90GB"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0025|cit25","unstructured":"A phase 2a randomised, double-blind, placebo-controlled repeat dose trial of the activity of MDT-637 in healthy subjects challenged with RSV-A (Memphis 37b) - phase 2a trial of MDT-637 in healthy subjects challenged with RSV trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012%E2%80%90001107%E2%80%9020%E2%80%90GB"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0026|cit26","unstructured":"A randomised, phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered ALS-008176 against respiratory syncytial virus infection in the virus challenge model - phase 2a, double blind, placebo-controlled, viral challenge study trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013%E2%80%90004036%E2%80%9030%E2%80%90GB"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0027|cit27","unstructured":"A phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the antiviral activity, safety, and pharmacokinetics of repeated doses of orally administered JNJ-53718678 against respiratory syncytial virus infection in the virus challenge model in healthy adult subjects trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2014%E2%80%90005041%E2%80%9041%E2%80%90GB"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0028|cit28","unstructured":"A randomised, phase 2a, double-blind, placebo-controlled study to evaluate the safety and antiviral activity against respiratory syncytial virus infection, and the pharmacokinetics of multiple oral doses of BTA-C585 in the virus challenge model trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015%E2%80%90004296%E2%80%9077%E2%80%90GB"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0029|cit29","unstructured":"A study to evaluate safety, reactogenicity and immunogenicity of GSK biologicals\u2019 RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive infants trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016%E2%80%90000117%E2%80%9076%E2%80%90ES"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0030|cit30","unstructured":"A study to evaluate safety and immunogenicity of GSK biologicals\u2019 RSV investigational vaccine in RSV-seropositive infants aged 12 to 23 months trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016%E2%80%90000117%E2%80%9076%E2%80%90PL"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0031|cit31","unstructured":"A study to rank different dosages of antigen of GlaxoSmithKline (GSK) biologicals\u2019 investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A), based on their immune response and safety, when administered to healthy adult women trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016%E2%80%90001135%E2%80%9012%E2%80%90FR"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0032|cit32","unstructured":"A study to evaluate the safety, reactogenicity and immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothers trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016%E2%80%90002733%E2%80%9030%E2%80%90ES"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0033|cit33","unstructured":"A study to evaluate different dose levels of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccine (GSK3888550A), based on the safety of the vaccine and the antibodies (body defences) that the body produces following the vaccine administration, when given to healthy non-pregnant women trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018%E2%80%90001340%E2%80%9062%E2%80%90FI"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"e00157","DOI":"10.1128\/CVI.00157-17","article-title":"Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses","volume":"24","author":"Falloon","year":"2017","journal-title":"Clinical and Vaccine Immunology"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"Journal of Infectious Diseases"},{"issue":"13","key":"10.1002\/14651858.CD002190.pub6-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0264-410X(96)00030-8","article-title":"Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60","volume":"14","author":"Falsey","year":"1996","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1086\/592168","article-title":"Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines - nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals","volume":"198","author":"Falsey","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl","key":"10.1002\/14651858.CD002190.pub6-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/ofid\/ofz360.2315","article-title":"Third trimester immunization with an respiratory syncytial virus F protein vaccine for the prevention of RSV lower respiratory tract infection in infants","volume":"6","author":"Fries","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti","year":"1969","journal-title":"American Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/infdis\/jiv406","article-title":"A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age","volume":"213","author":"Glenn","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/INF.0b013e318199c3b1","article-title":"Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children","volume":"28","author":"Gomez","year":"2009","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"17","key":"10.1002\/14651858.CD002190.pub6-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0264-410X(99)00527-7","article-title":"Evaluation of the live attenuated cpts 248\/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults","volume":"18","author":"Gonzalez","year":"2000","journal-title":"Vaccine"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1086\/428092","article-title":"A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy","volume":"191","author":"Greenberg","year":"2005","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/infdis\/132.6.623","article-title":"Human responses to two decavalent rhinovirus vaccines","volume":"132","author":"Hamory","year":"1975","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002190.pub6-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/ofid\/ofw172.513","article-title":"Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study","volume":"3","author":"Israel","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"issue":"22","key":"10.1002\/14651858.CD002190.pub6-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.vaccine.2019.04.026","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age","volume":"37","author":"Karppinen","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/infdis\/171.5.1107","article-title":"A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children","volume":"171","author":"Karron","year":"1995","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/infdis\/172.6.1445","article-title":"A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children","volume":"172","author":"Karron","year":"1995","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/514138","article-title":"Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children","volume":"176","author":"Karron","year":"1997","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/01.inf.0000066244.31769.83","article-title":"A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants","volume":"22","author":"Karron","year":"2003","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/427813","article-title":"Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants","volume":"191","author":"Karron","year":"2005","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Karron RA San Mateo J Thumar B Schaap-Nutt A Buchholz UJ Schmidt AC Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children Journal of Pediatric Infectious Diseases Society 2015 4 4 e143 6 10.1093\/jpids\/piu104 26582883","DOI":"10.1093\/jpids\/piu104"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1164\/rccm.202005-1660OC","article-title":"Live-attenuated vaccines prevent respiratory syncytial virus-associated illness in young children","volume":"203","author":"Karron","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial virus vaccine RSV\/DELTANS2\/DELTA1313\/I1314L in RSV-seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3920\/BM2014.0164","article-title":"Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: randomised, double blind, placebo-controlled pilot trial","volume":"6","author":"Kumpu","year":"2015","journal-title":"Beneficial Microbes"},{"issue":"42","key":"10.1002\/14651858.CD002190.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1016\/j.vaccine.2009.07.038","article-title":"A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or = 65 years of age","volume":"27","author":"Langley","year":"2009","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"ofw172.97","DOI":"10.1093\/ofid\/ofw172.973","article-title":"A phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of two intramuscular doses of DPXRSV (A), a respiratory syncytial virus (RSV) vaccine containing RSV SH antigen and a novel adjuvant depovax, or SH antigen and a novel adjuvant DepoVax, or SH antigen co-administered with aluminum hydroxide, or placebo to healthy adults \u2265 50\u201364 years of age","volume":"3","author":"Langley","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/infdis\/jiw453","article-title":"A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant","volume":"215","author":"Langley","year":"2017","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/infdis\/jiy177","article-title":"A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study","volume":"218","author":"Langley","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/323150","article-title":"Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants","volume":"184","author":"Lee","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.antiviral.2004.04.005","article-title":"Experimental infection of humans with A2 respiratory syncytial virus","volume":"63","author":"Lee","year":"2004","journal-title":"Antiviral Research"},{"issue":"20","key":"10.1002\/14651858.CD002190.pub6-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.vaccine.2019.04.011","article-title":"Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study","volume":"37","author":"Leroux-Roels","year":"2019","journal-title":"Vaccine"},{"issue":"23","key":"10.1002\/14651858.CD002190.pub6-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.vaccine.2008.03.037","article-title":"A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults","volume":"26","author":"Lyons","year":"2008","journal-title":"Vaccine"},{"issue":"13","key":"10.1002\/14651858.CD002190.pub6-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.vaccine.2005.12.002","article-title":"Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers","volume":"24","author":"Madhi","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/infdis\/jiy040","article-title":"Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children","volume":"217","author":"McFarland","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/infdis\/jiz603","article-title":"Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children","volume":"221","author":"McFarland","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD002190.pub6-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/infdis\/jiaa049","article-title":"Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children","volume":"221","author":"McFarland","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"24","key":"10.1002\/14651858.CD002190.pub6-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/S0264-410X(03)00352-9","article-title":"Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women","volume":"21","author":"Munoz","year":"2003","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/infdis\/jiz390","article-title":"Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants","volume":"220","author":"Mu\u0148oz","year":"2019","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0168-1702(94)90059-0","article-title":"An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines","volume":"32","author":"Murphy","year":"1994","journal-title":"Virus Research"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0072|cit72","unstructured":"A multi-country & multi-center study to assess the efficacy, immunogenicity & safety of two doses of GSK biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants clinicaltrials.gov\/show\/NCT00139347"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0073|cit73","unstructured":"Safety of and immune response to a human parainfluenza virus vaccine (rHPIV3cp45) in healthy infants clinicaltrials.gov\/show\/NCT00308412"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0074|cit74","unstructured":"Study to evaluate the safety of MEDI-534 vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) in healthy children clinicaltrials.gov\/show\/NCT00345670"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0075|cit75","unstructured":"To evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Bio HRV liquid vaccine given to infants (Vietnam) clinicaltrials.gov\/show\/NCT00345956"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0076|cit76","unstructured":"To assess immunogenicity, reactogenicity & safety of 2 formulations of GSK's HRV vaccine as 2-dose vaccination (Infants) clinicaltrials.gov\/ct2\/show\/NCT00363545"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0077|cit77","unstructured":"Safety of and immune response to a cow\/human parainfluenza virus vaccine (rB\/HPIV3) in healthy infants, children, and adults clinicaltrials.gov\/ct2\/show\/NCT00366782"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0078|cit78","unstructured":"Evaluate safety & immunogenicity of 2 or 3 doses of GSK HRV vaccine in healthy infants in South Africa clinicaltrials.gov\/ct2\/show\/NCT00383903"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0079|cit79","unstructured":"Long-term efficacy and safety of subjects approximately 3 years after priming with 2 doses of GSK Bio's HRV vaccine clinicaltrials.gov\/ct2\/show\/NCT00420316"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0080|cit80","unstructured":"Intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with respiratory syncytial virus clinicaltrials.gov\/ct2\/show\/NCT00496821"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0081|cit81","unstructured":"Safety of and immune response to recombinant live-attenuated parainfluenza type 1 virus vaccine clinicaltrials.gov\/ct2\/show\/NCT00641017"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0082|cit82","unstructured":"A study to evaluate the safety, tolerability, immunogenicity and vaccine-like viral shedding of MEDI-534, against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy 6 to < 24 month-old children and in 2 month-old infants clinicaltrials.gov\/ct2\/show\/NCT00686075"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0083|cit83","unstructured":"A randomized, double-blind, placebo-controlled study to evaluate safety of MEDI-559 in healthy 1 to < 24 month-old children clinicaltrials.gov\/ct2\/show\/NCT00767416"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0084|cit84","unstructured":"Safety of and immune response to recombinant live attenuated parainfluenza type 3 virus vaccine in healthy infants and children clinicaltrials.gov\/ct2\/show\/NCT01021397"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0085|cit85","unstructured":"Safety of a live attenuated human parainfluenza virus type 2 (HPIV2) vaccine for adults, children, and infants clinicaltrials.gov\/ct2\/show\/NCT01139437"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0086|cit86","unstructured":"Evaluating the safety and immunogenicity of a human parainfluenza type 3 (HPIV3) virus vaccine in infants and children clinicaltrials.gov\/ct2\/show\/NCT01254175"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0087|cit87","unstructured":"Safety study of respiratory syncytial virus (RSV)-fusion (F) protein particle vaccine clinicaltrials.gov\/ct2\/show\/NCT01290419"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0088|cit88","unstructured":"Intranasal challenge of healthy adults with respiratory syncytial virus (RSV) clinicaltrials.gov\/ct2\/show\/NCT01475305"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0089|cit89","unstructured":"RSV-F vaccine and influenza vaccine co-administration study in the elderly clinicaltrials.gov\/ct2\/show\/NCT01709019"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0090|cit90","unstructured":"Evaluating the safety and immune response to a single dose of a respiratory syncytial virus (RSV) vaccine in RSV-seronegative infants and children clinicaltrials.gov\/ct2\/show\/NCT01852266"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0091|cit91","unstructured":"Study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccines clinicaltrials.gov\/ct2\/show\/NCT01905215"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0092|cit92","unstructured":"A study to evaluate the safety of the respiratory syncytial virus vaccine MEDI7510 in older adults clinicaltrials.gov\/ct2\/show\/NCT02115815"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0093|cit93","unstructured":"Placebo-controlled study to evaluate the safety and immunogenicity of the RSV-F vaccine in elderly adults clinicaltrials.gov\/ct2\/show\/NCT02266628"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0094|cit94","unstructured":"A phase I randomized, observer-blinded, dose-ranging study in healthy subjects 24 to < 72 months of age clinicaltrials.gov\/ct2\/show\/NCT02296463"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0095|cit95","unstructured":"Trial to evaluate the safety, tolerability and immunogenicity of the recombinant MVA BN\u00ae RSV vaccine clinicaltrials.gov\/ct2\/show\/NCT02419391"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0096|cit96","unstructured":"A study to evaluate the safety, tolerability and immunogenicity of Ad35.RSV.FA2 regimens boosted with Ad26.RSV.FA2 in healthy adult participants clinicaltrials.gov\/ct2\/show\/NCT02440035\u00a0"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0097|cit97","unstructured":"A study to evaluate the safety and reactogenicity of DPX-RSV(A), a respiratory syncytial virus clinicaltrials.gov\/ct2\/show\/NCT02472548"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0098|cit98","unstructured":"Evaluation of ColdZyme\u00ae on experimentally induced common cold clinicaltrials.gov\/ct2\/show\/NCT02479750"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0099|cit99","unstructured":"A study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) biologicals' RSV investigational vaccine (ChAd155-RSV) (GSK3389245A) in healthy adults clinicaltrials.gov\/ct2\/show\/NCT02491463"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0100|cit100","unstructured":"A study to evaluate the safety, tolerability and immunogenicity of Ad26.RSV.FA2 followed by Ad35.RSV.FA2 in healthy adult volunteers clinicaltrials.gov\/ct2\/show\/NCT02561871"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0101|cit101","unstructured":"Safety and immunogenicity of the RSV-F vaccine in older adults previously treated with the same vaccine or placebo in the prior year clinicaltrials.gov\/ct2\/show\/NCT02593071"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0102|cit102","unstructured":"Safety and immunogenicity of the RSV D46cp\u0394M2-2 Vaccine in RSV-seropositive children and RSV-seronegative infants and children clinicaltrials.gov\/ct2\/show\/NCT02601612"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0103|cit103","unstructured":"A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization clinicaltrials.gov\/ct2\/show\/NCT02624947"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0104|cit104","unstructured":"Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine in RSV-seronegative infants 6 to 24 months of age clinicaltrials.gov\/ct2\/show\/NCT02794870"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0105|cit105","unstructured":"Dose-ranging trial of safety & immunogenicity of an oral adenoviral-vector based RSV vaccine (VXA-RSV-f) clinicaltrials.gov\/ct2\/show\/NCT02830932"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0106|cit106","unstructured":"RSV-MVA-BN vaccine phase I trial, intranasal application in adults clinicaltrials.gov\/ct2\/show\/NCT02864628"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0107|cit107","unstructured":"RSV-MVA-BN vaccine phase II trial in \u2265 55 year old adults clinicaltrials.gov\/ct2\/show\/NCT02873286"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0108|cit108","unstructured":"Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine (RSV LID cp \u0394M2-2) in RSV-seronegative infants 6 to 24 months of age clinicaltrials.gov\/ct2\/show\/NCT02890381"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0109|cit109","unstructured":"A study to evaluate the safety, tolerability and immunogenicity of two vaccinations of Ad26.RSV.preF one year apart in adults aged 60 years and older in stable health clinicaltrials.gov\/ct2\/show\/NCT02926430"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0110|cit110","unstructured":"Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine (RSV LID cp \u0394M2-2) in RSV-seronegative infants 6 to 24 months of age clinicaltrials.gov\/ct2\/show\/NCT02952339"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0111|cit111","unstructured":"Safety and immunogenicity study to evaluate single- or two-dose regimens of RSV F vaccine with and without aluminum phosphate or Matrix-M1\u2122 adjuvants in clinically-stable older adults clinicaltrials.gov\/ct2\/show\/NCT03026348"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0112|cit112","unstructured":"Dose, safety, tolerability and immunogenicity of a stabilized prefusion RSV F subunit protein vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), alone or with alum adjuvant, in healthy adults clinicaltrials.gov\/ct2\/show\/NCT03049488"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0113|cit113","unstructured":"A study to evaluate the safety, reactogenicity and immunogenicity of the GlaxoSmithKline (GSK) biologicals' respiratory syncytial virus (RSV) investigational vaccine (GSK3003891A) in healthy pregnant women and infants born to vaccinated mothers clinicaltrials.gov\/ct2\/show\/NCT03191383"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0114|cit114","unstructured":"A study to evaluate the safety, tolerability and immunogenicity of an investigational RSV vaccine candidate (Ad26.RSV.preF) in adults 18 to 50 years of age, and RSV-seropositive toddlers 12 to 24 months of age clinicaltrials.gov\/ct2\/show\/NCT03303625"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0115|cit115","unstructured":"An exploratory study to evaluate the prophylactic efficacy of a single immunization of Ad26.RSV.preF against respiratory syncytial virus infection in a virus challenge model in healthy 18 to 50 year-old adults clinicaltrials.gov\/ct2\/show\/NCT03334695"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0116|cit116","unstructured":"Safety, reactogenicity, and immunogenicity of mRNA-1653 in healthy adults clinicaltrials.gov\/ct2\/show\/NCT03392389"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0117|cit117","unstructured":"A first-in-human study of orally administered JNJ-64417184 to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses, and the antiviral activity of multiple doses in a respiratory syncytial virus (RSV) challenge study in healthy participants clinicaltrials.gov\/ct2\/show\/NCT03403348"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0118|cit118","unstructured":"A safety and immunogenicity study of intranasal sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine in healthy adults clinicaltrials.gov\/ct2\/show\/NCT03473002"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0119|cit119","unstructured":"A study to evaluate the safety and immunogenicity of an adjuvanted RSV vaccine in healthy older adults clinicaltrials.gov\/ct2\/show\/NCT03572062"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0120|cit120","unstructured":"A study to evaluate different dose levels of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccine (GSK3888550A), based on the vaccine safety and the antibodies (body defences) produced following vaccine administration clinicaltrials.gov\/ct2\/show\/NCT03674177"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0121|cit121","unstructured":"A study to assess the safety, reactogenicity and immune response of GlaxoSmithKline (GSK) biologicals' investigational respiratory syncytial virus (RSV) vaccine (GSK3844766A) in older adults clinicaltrials.gov\/ct2\/show\/NCT03814590"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0122|cit122","unstructured":"A study of a RSV vaccines when given together with TDAP in healthy non-pregnant women aged between 18 to 49 years clinicaltrials.gov\/ct2\/show\/NCT04071158"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0123|cit123","unstructured":"Phase 2a respiratory syncytial virus (RSV) human challenge study of MK-1654 in healthy participants (MK-1654-005) clinicaltrials.gov\/ct2\/show\/NCT04086472"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0124|cit124","unstructured":"Phase 2a study of MVA-BN-RSV vaccination and RSV challenge in healthy adults clinicaltrials.gov\/ct2\/show\/NCT04752644"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0125|cit125","unstructured":"Clinical study to evaluate safety, tolerability and effects on the immune system of a common cold vaccine in healthy adults www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR7173"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00006454-199409000-00008","article-title":"Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old","volume":"13","author":"Paradiso","year":"1994","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002190.pub6-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/ofid\/ofw194.131","article-title":"Effect of febrile rhinovirus illness during pregnancy on adverse birth outcomes in Nepal","volume":"3","author":"Philpott","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"ofx073","DOI":"10.1093\/ofid\/ofx073","article-title":"Febrile rhinovirus illness during pregnancy is associated with low birth weight in Nepal","volume":"4","author":"Philpott","year":"2017","journal-title":"Open Forum Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD002190.pub6-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/0264-410X(95)00034-X","article-title":"Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection","volume":"13","author":"Piedra","year":"1995","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/oxfordjournals.aje.a120805","article-title":"Live and inactivated adenovirus vaccines for the prevention of acute respiratory illness in naval recruits","volume":"87","author":"Pierce","year":"1968","journal-title":"American Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1086\/324426","article-title":"Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults","volume":"184","author":"Power","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"7021","key":"10.1002\/14651858.CD002190.pub6-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(58)90870-5","article-title":"Autogenous vaccine in prophylaxis of the common cold","volume":"1","author":"Ritchie","year":"1958","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S2213-2600(21)00098-9","article-title":"Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial","volume":"9","author":"Ruckwardt","year":"2021","journal-title":"Lancet Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/infdis\/jiab003","article-title":"Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study","volume":"226","author":"Sadoff","year":"2022","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/infdis\/jiaa409","article-title":"Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults","volume":"223","author":"Sadoff","year":"2021","journal-title":"Journal of Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.vaccine.2020.01.055","article-title":"Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase I clinical trial","volume":"38","author":"Samy","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/21645515.2020.1779517","article-title":"Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults","volume":"17","author":"Scaggs Huang","year":"2021","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1093\/infdis\/jiz395","article-title":"Immunogenicity and safety of 3 formulations of a respiratory syncytial virus candidate vaccine in non-pregnant women: a phase II, randomized trial","volume":"220","author":"Schwarz","year":"2019","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ajog.2019.10.080","article-title":"Immunoglobulin A, immunoglobulin G, and neutralizing antibodies to respiratory syncytial virus increase in human milk following immunization with an RSV F protein vaccine","volume":"221","author":"Shakib","year":"2019","journal-title":"International Journal of Stroke"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002190.pub6-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"S970","DOI":"10.1093\/ofid\/ofz360.2431","article-title":"Phase 1 trial of an mRNA-based combination vaccine against HMPV and PIV3","volume":"6","author":"Shaw","year":"2019","journal-title":"Open Forum Infectious Diseases"},{"issue":"5-6","key":"10.1002\/14651858.CD002190.pub6-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0264-410X(01)00388-7","article-title":"Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines","volume":"20","author":"Simoes","year":"2001","journal-title":"Vaccine"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.ajog.2019.10.081","article-title":"Safety of third trimester immunization with a respiratory syncytial virus F protein vaccine and protection of infants over the first 180 days of life against all-cause lower respiratory tract infection","volume":"221","author":"Swamy","year":"2019","journal-title":"American Journal of Obstetrics & Gynecology"},{"issue":"50","key":"10.1002\/14651858.CD002190.pub6-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1016\/j.vaccine.2008.09.018","article-title":"Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults","volume":"26","author":"Tang","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/infdis\/124.2.155","article-title":"Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7","volume":"124","author":"Buescher","year":"1971","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/infdis\/167.1.191","article-title":"Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old","volume":"167","author":"Tristram","year":"1993","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/bcp.14266","article-title":"First-in-human, randomized study to assess the safety, tolerability, immunogenicity, and shedding of a live attenuated respiratory syncytial virus vaccine","volume":"86","author":"Van Der Plas","year":"2020","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"39","key":"10.1002\/14651858.CD002190.pub6-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.1016\/j.vaccine.2020.07.029","article-title":"First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial","volume":"38","author":"Verdijk","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0264-410X(90)90051-M","article-title":"Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines","volume":"8","author":"Watt","year":"1990","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/infdis\/170.2.425","article-title":"Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine","volume":"170","author":"Welliver","year":"1994","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged \u2265 60 years","volume":"222","author":"Williams","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"5179","key":"10.1002\/14651858.CD002190.pub6-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.1.5179.1081","article-title":"Trial of adenovirus vaccine in Royal Air Force recruits","volume":"1","author":"Wilson","year":"1960","journal-title":"British Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0022-3476(76)81044-X","article-title":"Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants","volume":"88","author":"Wright","year":"1976","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jval.2019.09.2747","article-title":"Evaluation of efficacy endpoints for a phase IIb study of a respiratory syncytial virus vaccine in older adults using patient-reported outcomes with laboratory confirmation","volume":"23","author":"Yu","year":"2020","journal-title":"Value Health"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0154|cit154","unstructured":"Evaluating the safety and immune response to a single dose of a respiratory syncytial virus (RSV) vaccine in infants and children clinicaltrials.gov\/ct2\/show\/NCT01893554"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0155|cit155","unstructured":"Evaluating the infectivity, safety, and immunogenicity of a respiratory syncytial virus vaccine (RSV 6120\/\u2206NS2\/1030s) in RSV-seropositive children and RSV-seronegative infants and children clinicaltrials.gov\/ct2\/show\/NCT03387137"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0156|cit156","unstructured":"Evaluating the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV \u0394NS2\/\u03941313\/I1314L or RSV 276 in RSV-seronegative infants and children 6 to 24 months of age clinicaltrials.gov\/ct2\/show\/NCT03422237"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0157|cit157","unstructured":"Evaluating the infectivity, safety and immunogenicity of respiratory syncytial virus vaccines, RSV 6120\/\u2206NS1 and RSV 6120\/F1\/G2\/\u2206NS1, in RSV-seropositive children and RSV-seronegative infants and children clinicaltrials.gov\/ct2\/show\/NCT03596801"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0158|cit158","unstructured":"Safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV \u0394NS2\/\u03941313\/I1314L, RSV 6120\/\u0394NS2\/1030s, RSV 276 or placebo, delivered as nose drops to RSV-seronegative children 6 to 24 months of age clinicaltrials.gov\/ct2\/show\/NCT03916185\u00a0"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0159|cit159","unstructured":"A phase 2B placebo-controlled, randomized study of a respiratory syncytial virus (RSV) vaccine in pregnant women clinicaltrials.gov\/ct2\/show\/NCT04032093"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0160|cit160","unstructured":"Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) respiratory syncytial virus (RSV) maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants clinicaltrials.gov\/ct2\/show\/NCT04126213"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0161|cit161","unstructured":"A study of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccine against diphtheria, pertussis and tetanus (Tdap) viruses followed by a 2nd dose of the RSV vaccine to healthy non-pregnant women clinicaltrials.gov\/ct2\/show\/NCT04138056"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0162|cit162","unstructured":"Safety and efficacy of BARS13 in the elderly clinicaltrials.gov\/ct2\/show\/NCT04681833"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0163|cit163","unstructured":"Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 years and above clinicaltrials.gov\/ct2\/show\/NCT04732871"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0164|cit164","unstructured":"A study on the safety and immune response to an unadjuvanted RSV maternal vaccine, in high-risk pregnant women aged 15 to 49 years and infants born to the vaccinated mothers clinicaltrials.gov\/ct2\/show\/NCT04980391"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0165|cit165","unstructured":"A study to evaluate the safety and efficacy of mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in adults \u226560 years of age clinicaltrials.gov\/ct2\/show\/NCT05127434"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0166|cit166","unstructured":"Phase 3 MVA-BN-RSV vaccine efficacy trial clinicaltrials.gov\/ct2\/show\/NCT05238025"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0167|cit167","volume-title":"Basic Immunology","volume":"1","author":"Abbas","year":"2001"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"e0199388","DOI":"10.1371\/journal.pone.0199388","article-title":"Transmission of rhinovirus in the Utah BIG-LoVE families: consequences of age and household structure","volume":"13","author":"Adler","year":"2018","journal-title":"PLOS ONE"},{"issue":"7438","key":"10.1002\/14651858.CD002190.pub6-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/bmj.328.7438.476","article-title":"Absence of evidence is not evidence of absence","volume":"328","author":"Alderson","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/fampra\/cmw002","article-title":"Risk factors for respiratory infections among children attending day care centres","volume":"33","author":"Alexandrino","year":"2016","journal-title":"Family Practice"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1503\/cmaj.121442","article-title":"Prevention and treatment of the common cold: making sense of the evidence","volume":"186","author":"Allan","year":"2014","journal-title":"Canadian Medical Association Journal"},{"issue":"7003","key":"10.1002\/14651858.CD002190.pub6-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.311.7003.485","article-title":"Absence of evidence is not evidence of absence","volume":"311","author":"Altman","year":"1995","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/infdis\/jiw023","article-title":"A randomized, controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants","volume":"213","author":"Armah","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1128\/jcm.35.11.2864-2868.1997","article-title":"Frequency and natural history of rhinovirus infections in adults during autumn","volume":"35","author":"Arruda","year":"1997","journal-title":"Journal of Clinical Microbiology"},{"issue":"7454","key":"10.1002\/14651858.CD002190.pub6-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD002190.pub6-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/clinids\/13.Supplement_6.S454","article-title":"Epidemiology of acute respiratory infections in children of developing countries","volume":"13","author":"Berman","year":"1991","journal-title":"Reviews of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/vaccines8040602","article-title":"Immune response against adenovirus in acute upper respiratory tract infections in immunocompetent children","volume":"8","author":"Biserni","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/infdis\/jiy066","article-title":"Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children","volume":"217","author":"Buchholz","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/infdis\/jiu316","article-title":"Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh","volume":"210","author":"Chu","year":"2014","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/vaccines8030411","article-title":"Live oral adenovirus type 4 and type 7 vaccine induces durable antibody response","volume":"8","author":"Collins","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"109","DOI":"10.17219\/acem\/129573","article-title":"Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: a systematic literature review","volume":"30","author":"Czubak","year":"2021","journal-title":"Advances in Clinical and Experimental Medicine"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0182|cit182","unstructured":"Division of Disease Control and Prevention Utah Department of Health Difference between cold and flu symptoms health.utah.gov\/epi\/diseases\/flu\/ColdvsFlu.pdf"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0183|cit183","first-page":"281","article-title":"Treatment of the common cold","volume":"100","author":"DeGeorge","year":"2019","journal-title":"American Family Physician"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1542\/peds.71.6.871","article-title":"Croup: an 11 year study in a pediatric practice","volume":"71","author":"Denny","year":"1983","journal-title":"Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD002190.pub6-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1185\/03007995.2015.1062355","article-title":"Impact of cough and common cold on productivity, absenteeism, and daily life in the United States: ACHOO Survey","volume":"31","author":"Dicpinigaitis","year":"2015","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"23\u201345","DOI":"10.1007\/978-3-7643-9912-2_2","article-title":"Mechanisms of symptoms of common cold and flu","volume":"10","author":"Eccles","year":"2009","journal-title":"Common Cold"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1183\/09031936.00149109","article-title":"Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation","volume":"37","author":"Edlmayr","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD002190.pub6-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1542\/peds.111.6.1407","article-title":"Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children","volume":"111","author":"Esper","year":"2003","journal-title":"Pediatrics"},{"issue":"17","key":"10.1002\/14651858.CD002190.pub6-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD002190.pub6-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1056\/NEJM197809282991304","article-title":"The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 \"negative\" trials","volume":"299","author":"Freiman","year":"1978","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMp1207437","article-title":"Getting the methods right - the foundation of patient-centered outcomes research","volume":"367","author":"Gabriel","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijid.2020.05.001","article-title":"Comparison of mortality associated with respiratory viral infections between December 2019 and March 2020 with that of the previous year in Southeastern France","volume":"96","author":"Giraud-Gatineau","year":"2020","journal-title":"International Society for Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"e1003669","DOI":"10.1371\/journal.ppat.1003669","article-title":"Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein","volume":"9","author":"Glanville","year":"2013","journal-title":"PLOS Pathogens"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0194|cit194","volume-title":"Kuby Immunology","volume":"3","author":"Goldsby","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/vaccines5010006","article-title":"Harnessing nanoparticles for immunomodulation and vaccines","volume":"5","author":"Gomes","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0196|cit196","volume-title":"Inmunolog\u00eda Basada en la Resoluci\u00f3n de Problemas","volume":"138","author":"Gorczynski","year":"2007"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0197|cit197","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/epirev\/24.1.4","article-title":"Design of randomized trials","volume":"24","author":"Green","year":"2002","journal-title":"Epidemiologic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jama.1967.03130190100014","article-title":"Rhinovirus infections in an industrial population II. Characteristics of illness and antibody response","volume":"202","author":"Gwaltney","year":"1967","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0200|cit200","first-page":"265","article-title":"Virology and immunology of the common cold","volume":"23","author":"Gwaltney","year":"1985","journal-title":"Rhinology"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0201|cit201","first-page":"651","volume-title":"Principles and Practices of Infectious Diseases","author":"Gwaltney","year":"2000"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0202|cit202","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006895.pub3","article-title":"Probiotics for preventing acute upper respiratory tract infections","author":"Hao","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9351","key":"10.1002\/14651858.CD002190.pub6-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(03)12162-9","article-title":"The common cold","volume":"361","author":"Heikkinen","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/CMR.16.2.242-264.2003","article-title":"Parainfluenza viruses","volume":"16","author":"Henrickson","year":"2003","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0205|cit205","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0206|cit206","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"3-4","key":"10.1002\/14651858.CD002190.pub6-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jrsm.19","article-title":"Meta-research: the art of getting it wrong","volume":"1","author":"Ioannidis","year":"2010","journal-title":"Research Synthesis Methods"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11882-020-00917-5","article-title":"Common cold and acute rhinosinusitis: up-to-date management in 2020","volume":"20","author":"Jaume","year":"2020","journal-title":"Current Allergy and Asthma Reports"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"481","DOI":"10.18176\/jiaci.0525","article-title":"Direct costs of acute rhinosinusitis in Spain - a prospective and observational study (PROSINUS)","volume":"31","author":"Jaume","year":"2021","journal-title":"Journal of Investigational Allergology and Clinical Immunology"},{"issue":"8","key":"10.1002\/14651858.CD002190.pub6-BIB0210|cit210","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004879.pub4","article-title":"Vaccines for preventing influenza in healthy children","author":"Jefferson","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0211|cit211","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006207.pub5","article-title":"Physical interventions to interrupt or reduce the spread of respiratory viruses","author":"Jefferson","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/COPD.S127146","article-title":"Colds as predictors of the onset and severity of COPD exacerbations","volume":"12","author":"Johnston","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00001432-200306000-00012","article-title":"Human metapneumovirus: a newly emerging respiratory pathogen","volume":"16","author":"Kahn","year":"2003","journal-title":"Current Opinion in Infection Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10059-009-0015-1","article-title":"Host responses from innate to adaptive immunity after vaccination: molecular and cellular events","volume":"27","author":"Kang","year":"2009","journal-title":"Molecular Cell"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0042-116112","article-title":"Common cold - an umbrella term for acute infections of nose, throat, larynx and bronchi","volume":"71","author":"Kardos","year":"2017","journal-title":"Pneumologie"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/INF.0b013e31822ea24f","article-title":"The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children","volume":"30","author":"Karron","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5694\/j.1326-5377.2002.tb04759.x","article-title":"Determining the sample size in a clinical trial","volume":"177","author":"Kirby","year":"2002","journal-title":"Medical Journal of Australia"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cmi.2014.12.002","article-title":"Survival of rhinoviruses on human fingers","volume":"21","author":"L'Huillier","year":"2015","journal-title":"Clinical Microbiology and Infection"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"e929","DOI":"10.1542\/peds.2006-3703","article-title":"Community epidemiology of human metapneumovirus, human coronavirus NL63, and other respiratory viruses in healthy preschool-aged children using parent-collected specimens","volume":"120","author":"Lambert","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jmv.1890050306","article-title":"Isolation of rhinoviruses and coronaviruses from 38 colds in adults","volume":"5","author":"Larson","year":"1980","journal-title":"Journal of Medical Virology"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/JCM.02614-05","article-title":"Coronavirus HKU1 and other coronavirus infection in Hong Kong","volume":"44","author":"Lau","year":"2006","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0222|cit222","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaci.2005.06.024","article-title":"Rhinovirus illnesses during infancy predict subsequent childhood wheezing","volume":"116","author":"Jackson","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"141580","DOI":"10.1016\/j.scitotenv.2020.141580","article-title":"Common cold among young adults in China without a history of asthma or allergic rhinitis - associations with warmer climate zone, dampness and mould at home, and outdoor PM10\u00a0and PM2.5","volume":"749","author":"Lu","year":"2020","journal-title":"Science of the Total Environment"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"ofaa385","DOI":"10.1093\/ofid\/ofaa385","article-title":"Molecular epidemiology of human rhinovirus from 1-year surveillance within a school setting in rural coastal Kenya","volume":"7","author":"Luka","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/JCM.36.2.539-542.1998","article-title":"Viruses and bacteria in the etiology of the common cold","volume":"36","author":"M\u00e4kel\u00e4","year":"1998","journal-title":"Journal of Clinical Microbiology"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0229|cit229","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.antiviral.2012.06.006","article-title":"Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1","volume":"95","author":"McLean","year":"2012","journal-title":"Antiviral Research"},{"issue":"9128","key":"10.1002\/14651858.CD002190.pub6-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"International Journal of Surgery"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1017\/S0950268800050779","article-title":"Acute respiratory illness in the community. Frequency of illness and the agents involved","volume":"110","author":"Monto","year":"1993","journal-title":"Epidemiology and Infection"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/infdis\/jiz390","article-title":"Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants","volume":"220","author":"Mu\u0148oz","year":"2019","journal-title":"Journal of Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD002190.pub6-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"7115","key":"10.1002\/14651858.CD002190.pub6-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/bmj.315.7115.1060","article-title":"Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective population based study of disease burden","volume":"315","author":"Nicholson","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5694\/j.1326-5377.2002.tb04354.x","article-title":"Evidence of human metapneumovirus in Australian children","volume":"176","author":"Nissen","year":"2002","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0238|cit238","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2020.08.008","article-title":"Cochrane centralised search service showed high sensitivity identifying randomized controlled trials: a retrospective analysis","volume":"127","author":"Noel-Storr","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0239|cit239","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jclinepi.2021.01.006","article-title":"An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials","volume":"133","author":"Noel-Storr","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jaci.2017.07.001","article-title":"Promising approaches for the treatment and prevention of viral respiratory illnesses","volume":"140","author":"Papadopoulos","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"15","key":"10.1002\/14651858.CD002190.pub6-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2012.466","article-title":"Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective","volume":"307","author":"Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI)","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1542\/peds.2008-3645","article-title":"Booster vaccinations: can immunologic memory outpace disease pathogenesis?","volume":"124","author":"Pichichero","year":"2009","journal-title":"Pediatrics"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0243|cit243","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clinical and Vaccine Immunology"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1183\/09031936.00076508","article-title":"Rhinovirus infections in infants: is respiratory syncytial virus ready for the challenge?","volume":"32","author":"Regamey","year":"2008","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"41601","DOI":"10.1038\/srep41601","article-title":"Genotyping of human rhinovirus in adult patients with acute respiratory infections identified predominant infections of genotype A21","volume":"7","author":"Ren","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0247|cit247","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/ijms18030556","article-title":"Immunological features of respiratory syncytial virus-caused pneumonia - implications for vaccine design","volume":"18","author":"Rey-Jurado","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0249|cit249","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/19338244.2015.1058234","article-title":"The healthy workplace project: reduced viral exposure in an office setting","volume":"71","author":"Reynolds","year":"2016","journal-title":"Archives of Environmental & Occupational Health"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0250|cit250","first-page":"2769","article-title":"Human metapneumovirus - occurrence and clinical significance","volume":"20","author":"Risnes","year":"2005","journal-title":"Tidsskrift for den Norske L\u00e6geforening"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0251|cit251","volume-title":"Essential Immunology","volume":"466","author":"Roitt","year":"2004"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0252|cit252","first-page":"25","article-title":"Colds and influenza: a review of diagnosis and conventional, botanical and nutritional considerations","volume":"12","author":"Roxas","year":"2007","journal-title":"Alternative Medicine Review"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaci.2016.03.049","article-title":"Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence","volume":"139","author":"Rubner","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"15","key":"10.1002\/14651858.CD002190.pub6-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.vaccine.2005.12.062","article-title":"Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004","volume":"24","author":"Russell","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"20","key":"10.1002\/14651858.CD002190.pub6-BIB0256|cit256","doi-asserted-by":"publisher","first-page":"e10729","DOI":"10.1097\/MD.0000000000010729","article-title":"Potential common factors associated with predisposition to common cold in middle-aged and elderly Japanese: a community-based cross-sectional study","volume":"97","author":"Shibata","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14760584.2019.1657014","article-title":"Overview of human rhinovirus immunogenic epitopes for rational vaccine design","volume":"18","author":"Stepanova","year":"2019","journal-title":"Expert Review of Vaccines"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0258|cit258","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4104\/pcrj.2012.00011","article-title":"High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care","volume":"21","author":"Stj\u00e4rne","year":"2012","journal-title":"Primary Care Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD002190.pub6-BIB0259|cit259","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3389\/fmicb.2017.02412","article-title":"Rhinovirus biology, antigenic diversity, and advancements in the design of a human rhinovirus vaccine","volume":"5","author":"Stobart","year":"2017","journal-title":"Frontiers in Microbiology"},{"issue":"15","key":"10.1002\/14651858.CD002190.pub6-BIB0260|cit260","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1745-6215-15-61","article-title":"An investigation of the impact of futility analysis in publicly funded trials","volume":"17","author":"Sully","year":"2014","journal-title":"Trials"},{"issue":"11","key":"10.1002\/14651858.CD002190.pub6-BIB0261|cit261","doi-asserted-by":"publisher","first-page":"e02503","DOI":"10.1128\/JVI.02503-16","article-title":"Structural characterization of human coronavirus NL63 N protein","volume":"91","author":"Szelazek","year":"2017","journal-title":"Journal of Virology"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12879-018-3662-z","article-title":"Diversity of upper respiratory tract infections and prevalence of Streptococcus pneumoniae colonization among patients with fever and flu-like symptoms","volume":"19","author":"Tang","year":"2019","journal-title":"BMC Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0263|cit263","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005187.pub4","article-title":"Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions","author":"Thomas","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002190.pub6-BIB0264|cit264","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2020.11.003","article-title":"Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews","volume":"133","author":"Thomas","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0266|cit266","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jfma.2017.04.009","article-title":"Rhinovirus - from bench to bedside","volume":"116","author":"To","year":"2017","journal-title":"Journal of the Formosan Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/02770903.2012.661009","article-title":"Association between episodes of upper respiratory infection and exacerbations in adult patients with asthma","volume":"49","author":"Tomita","year":"2012","journal-title":"Journal of Asthma"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0268|cit268","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12913-020-5021-1","article-title":"Cost of inappropriate antimicrobial use for upper respiratory infection in Japan","volume":"20","author":"Tsuzuki","year":"2020","journal-title":"BMC Health Services Research"},{"issue":"2","key":"10.1002\/14651858.CD002190.pub6-BIB0269|cit269","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/jmv.26362","article-title":"More than just a common cold: endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults","volume":"93","author":"Veiga","year":"2021","journal-title":"Journal of Medical Virology"},{"issue":"7","key":"10.1002\/14651858.CD002190.pub6-BIB0270|cit270","doi-asserted-by":"publisher","first-page":"e0180888","DOI":"10.1371\/journal.pone.0180888","article-title":"Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016","volume":"12","author":"Visseaux","year":"2017","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1002\/14651858.CD002190.pub6-BIB0271|cit271","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12931-019-1120-0","article-title":"Rhinovirus replication and innate immunity in highly differentiated human airway epithelial cells","volume":"20","author":"Warner","year":"2019","journal-title":"Respiratory Research"},{"issue":"3","key":"10.1002\/14651858.CD002190.pub6-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/ajcn\/nqaa165","article-title":"Absence of evidence is no evidence for absence of the phenomenon","volume":"112","author":"Westerterp","year":"2020","journal-title":"American Journal of Clinical Nutrition"},{"issue":"9","key":"10.1002\/14651858.CD002190.pub6-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1080\/21645515.2018.1476813","article-title":"The human vaccines project: towards a comprehensive understanding of the human immune response to immunization","volume":"14","author":"Wooden","year":"2018","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/INF.0000000000002660","article-title":"Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children","volume":"39","author":"Zimmermann","year":"2020","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nature Reviews Drug Discovery"},{"issue":"4","key":"10.1002\/14651858.CD002190.pub6-BIB0276|cit276","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002190.pub3","article-title":"Vaccines for the common cold","author":"Felix","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD002190.pub6-BIB0277|cit277","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002190.pub4","article-title":"Vaccines for the common cold","author":"Simancas-Racines","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD002190.pub6-BIB0278|cit278","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002190.pub4","article-title":"Vaccines for the common cold","author":"Simancas-Racines","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T02:48:32Z","timestamp":1747277312000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002190.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Acute Respiratory Infections Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":278,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002190.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]}}}